Published in Eur Radiol on January 22, 2010
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol (2016) 1.73
A systematic review of the utility of 1.5 versus 3 Tesla magnetic resonance brain imaging in clinical practice and research. Eur Radiol (2012) 1.64
Diagnostic relevance of high field MRI in clinical neuroradiology: the advantages and challenges of driving a sports car. Eur Radiol (2012) 1.33
Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology (2012) 1.07
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol (2015) 1.04
Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol (2012) 1.04
Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol (2011) 1.03
Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology (2012) 1.00
MS cortical lesions on DIR: not quite what they seem? PLoS One (2013) 0.99
Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR. Eur Radiol (2011) 0.96
Quantitative magnetic resonance imaging of cortical multiple sclerosis pathology. Mult Scler Int (2012) 0.90
The Holy Grail in diagnostic neuroradiology: 3T or 3D? Eur Radiol (2010) 0.88
Utility of double inversion recovery MRI in paediatric epilepsy. Br J Radiol (2015) 0.87
Comparison of 3D double inversion recovery and 2D STIR FLAIR MR sequences for the imaging of optic neuritis: pilot study. Eur Radiol (2014) 0.87
Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter. Eur Radiol (2012) 0.86
A comprehensive approach to the segmentation of multichannel three-dimensional MR brain images in multiple sclerosis. Neuroimage Clin (2013) 0.84
Advanced MRI in multiple sclerosis: current status and future challenges. Neurol Clin (2011) 0.83
MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update. Clin Neuroradiol (2015) 0.82
Identification of cortical lesions using DIR and FLAIR in early stages of multiple sclerosis. J Neurol (2015) 0.81
Removal of cerebrospinal fluid partial volume effects in quantitative magnetization transfer imaging using a three-pool model with nonexchanging water component. Magn Reson Med (2014) 0.81
Automated patient-specific optimization of three-dimensional double-inversion recovery magnetic resonance imaging. Magn Reson Med (2015) 0.81
Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. J Neurooncol (2013) 0.81
Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations. Mult Scler Int (2013) 0.80
Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol (2010) 0.79
Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis. J Magn Reson Imaging (2016) 0.79
Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period. PLoS One (2017) 0.75
Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis. J Neurol (2015) 0.75
Optimal detection of infratentorial lesions with a combined dual-echo MRI sequence: "PT2". Mult Scler (2015) 0.75
3D-DIR for early differential diagnostic and prognostic evaluation of NMO. Exp Ther Med (2016) 0.75
Cerebral vein changes in relapsing-remitting multiple sclerosis demonstrated by three-dimensional enhanced T₂-weighted angiography at 3.0 T. Eur Radiol (2012) 0.75
Olfactory dysfunction in neuromyelitis optica spectrum disorders. J Neurol (2015) 0.75
Altered signal intensity of active enhancing inflammatory lesions using post-contrast double inversion recovery MR sequence. Eur Radiol (2016) 0.75
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Cortical lesions in multiple sclerosis. Brain (1999) 2.83
Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol (2008) 2.65
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology (2005) 2.47
Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler (2003) 2.24
Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol (2000) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol (2007) 2.07
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Grey matter pathology in multiple sclerosis. Lancet Neurol (2008) 1.97
Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol (2000) 1.88
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol (2007) 1.76
First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7T. AJNR Am J Neuroradiol (2009) 1.65
In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology (2009) 1.64
Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology (2009) 1.35
High field MRI in the diagnosis of multiple sclerosis: high field-high yield? Neuroradiology (2009) 1.24
Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. Eur Radiol (2008) 1.22
Whole-body high-field-strength (3.0-T) MR Imaging in Clinical Practice. Part I. Technical considerations and clinical applications. Radiology (2008) 1.21
Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol (2004) 1.20
In vivo detection of cortical plaques by MR imaging in patients with multiple sclerosis. AJNR Am J Neuroradiol (2006) 1.16
Technical note: use of a double inversion recovery pulse sequence to image selectively grey or white brain matter. Br J Radiol (1994) 1.14
Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol (2006) 1.06
Double inversion recovery imaging of the brain: initial experience and comparison with fluid attenuated inversion recovery imaging. Magn Reson Imaging (1998) 1.06
Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. J Neurol (2008) 1.03
Isotropic 3D fast FLAIR imaging of the brain in multiple sclerosis patients: initial experience. Eur Radiol (2001) 0.98
Implementation and evaluation of a new pulse sequence for rapid acquisition of double inversion recovery images for simultaneous suppression of white matter and CSF. J Magn Reson Imaging (1998) 0.95
Signal abnormalities on 1.5 and 3 Tesla brain MRI in multiple sclerosis patients and healthy controls. A morphological and spatial quantitative comparison study. Neuroimage (2009) 0.92
Triple-layer appearance of Brodmann area 4 at thin-section double inversion-recovery MR imaging. Radiology (2008) 0.90
Double Inversion Recovery MRI with fat suppression at 7 tesla: initial experience. J Neuroimaging (2010) 0.89
The histopathology of grey matter demyelination in multiple sclerosis. Acta Neurol Scand Suppl (2009) 0.89
Epileptic and non-epileptic seizures in multiple sclerosis. J Neurol (2001) 0.86
Imaging of inflammatory lesions at 3.0 Tesla in patients with clinically isolated syndromes suggestive of multiple sclerosis: a comparison of fluid-attenuated inversion recovery with T2 turbo spin-echo. Eur Radiol (2006) 0.82
Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol (2006) 20.17
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol (2010) 6.61
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res (2010) 6.09
MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet (2007) 5.63
When to use agreement versus reliability measures. J Clin Epidemiol (2006) 5.24
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan: Response. Radiology (2017) 4.99
PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med (2015) 4.92
Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol (2005) 4.35
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol (2010) 4.10
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med (2013) 4.02
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol (2010) 3.46
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology (2006) 3.40
Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res (2011) 3.27
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Software-recorded and self-reported duration of computer use in relation to the onset of severe arm-wrist-hand pain and neck-shoulder pain. Occup Environ Med (2010) 2.89
Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change. Health Qual Life Outcomes (2006) 2.88
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Multidisciplinary rehabilitation for subacute low back pain: graded activity or workplace intervention or both? A randomized controlled trial. Spine (Phila Pa 1976) (2007) 2.74
Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab (2007) 2.68
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
In silico fragmentation for computer assisted identification of metabolite mass spectra. BMC Bioinformatics (2010) 2.61
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology (2005) 2.47
Fatal B-cell lymphoma following chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. JAMA Neurol (2013) 2.47
1H metabolite relaxation times at 3.0 tesla: Measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J Magn Reson Imaging (2004) 2.47
Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology (2012) 2.44
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Sentinel-lymph-node procedure in colon and rectal cancer: a systematic review and meta-analysis. Lancet Oncol (2011) 2.36
Multifactorial intervention to reduce falls in older people at high risk of recurrent falls: a randomized controlled trial. Arch Intern Med (2010) 2.34
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry (2013) 2.23
Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain (2010) 2.19
Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology (2005) 2.16
Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One (2010) 2.12
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol (2010) 1.98
Grey matter pathology in multiple sclerosis. Lancet Neurol (2008) 1.97
Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology (2012) 1.94
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke (2006) 1.88
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Evaluation of the methodological quality of systematic reviews of health status measurement instruments. Qual Life Res (2009) 1.82
Are we regionalized enough? Early-neonatal deaths in low-risk births by the size of delivery units in Hesse, Germany 1990-1999. Int J Epidemiol (2002) 1.82
Randomised controlled trial of integrated care to reduce disability from chronic low back pain in working and private life. BMJ (2010) 1.81
Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology (2007) 1.80
Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A (2004) 1.80
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Unusual variants of Alexander's disease. Ann Neurol (2005) 1.76
Effects of multidisciplinary integrated care on quality of care in residential care facilities for elderly people: a cluster randomized trial. CMAJ (2011) 1.75
On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke (2008) 1.75
First-pass and steady-state MR angiography of thoracic vasculature in children and adolescents. JACC Cardiovasc Imaging (2010) 1.74
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Global Perceived Effect scales provided reliable assessments of health transition in people with musculoskeletal disorders, but ratings are strongly influenced by current status. J Clin Epidemiol (2010) 1.69
Pathological consequences of VCP mutations on human striated muscle. Brain (2006) 1.68
No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. J Neurol Neurosurg Psychiatry (2010) 1.68
Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology (2010) 1.68
Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach. Qual Life Res (2006) 1.68
Sensitivity encoding for diffusion-weighted MR imaging at 3.0 T: intraindividual comparative study. Radiology (2005) 1.67
Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J Clin Oncol (2013) 1.67
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging (2008) 1.67
Thalamic involvement in sporadic Creutzfeldt-Jakob disease: a diffusion-weighted MR imaging study. AJNR Am J Neuroradiol (2003) 1.66
Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol (2002) 1.64
The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum (2011) 1.63
Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology (2012) 1.62
Implementation of clinical guidelines on physical therapy for patients with low back pain: randomized trial comparing patient outcomes after a standard and active implementation strategy. Phys Ther (2005) 1.62
Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. Ann Neurol (2005) 1.61
Will the real multiple sclerosis please stand up? Nat Rev Neurosci (2012) 1.61
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Model-free group analysis shows altered BOLD FMRI networks in dementia. Hum Brain Mapp (2009) 1.59